Kura Oncology, Inc. (KURA)

Over the past six months, Kura Oncology's stock experienced several significant events. KOMZIFTI received FDA approval in November 2025 and generated $2.1 million in net product revenue in Q4 2025. Kura received $135 million from Kyowa Kirin upon KOMZIFTI's first commercial sale and two $30 million milestone payments related to the KOMET-017 trial. The company reported a Q4 2025 loss of $0.92 per share, missing estimates, but highlighted a strong capital position. Enrollment continued in the KOMET-017 Phase 3 trials, and the FIT-001 Phase 1b dose expansion was initiated. KURA's stock has trended down by 11.98% in the past six months but up by 54.00% over the past year, with a consensus rating of "Moderate Buy".

Kura Oncology's products are not subject to traditional demand seasonality. Demand for oncology treatments is driven by disease incidence, diagnosis rates, and clinical efficacy, rather than seasonal patterns.

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, operating within the Healthcare sector, specifically in Biotechnology and Drug Discovery. Its pipeline includes KOMZIFTI (ziftomenib), approved for R/R NPM1-mutated AML and being evaluated in Phase 3 trials; Darlifarnib (KO-2806), an FTI in Phase 1 trials for solid tumors; KO-7246, a next-generation menin inhibitor; and Tipifarnib, an FTI for HRAS mutant head and neck cancer.

Kura Oncology is headquartered in San Diego, California, with an additional office in Boston, Massachusetts. Its primary operational focus is in the United States, but its stock is listed on several European exchanges, indicating a broader financial presence.

Kura Oncology's brand reputation has been shaped by clinical and commercial milestones and financial challenges. The FDA approval of KOMZIFTI and positive early market feedback have been positive. The collaboration with Kyowa Kirin has been viewed favorably. However, the company reported a significant miss in its Q4 2025 earnings and revenue, and faces competition from Syndax's Revuforj. There has also been some insider selling.

Kura Oncology has a mixed ownership structure. Approximately 68.01% of the stock is owned by institutional investors, including BlackRock, Inc., BVF Inc/il, and Vanguard Group Inc. Insiders own about 2.47%, with some insider selling and a significant purchase by Chairman Troy Wilson. Public companies and individual investors collectively own approximately 29.52% of the stock.